臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| Total items :2875249
	Visitors : 54238151 Online Users : 1557 Project Commissioned by the Ministry of Education Project Executed by National Taiwan University Library

Scope

Adv. Search

Login

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"m rten a"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 1-10 / 12 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2022-06-27T02:49:08Z	Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)	Popat S.; Hsia T.-C.; Hung J.-Y.; Jung H.A.; JIN-YUAN SHIH; Park C.K.; Lee S.H.; Okamoto T.; Ahn H.K.; Lee Y.C.; Sato Y.; Lee S.S.; Mascaux C.; Daoud H.; M?rten A.; Miura S.
臺大學術典藏	2021-04-23T05:56:29Z	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases	Chih-Hsin Yang;Schuler M.;Popat S.;Miura S.;Heeke S.;Park K.;M?Rten A.;Kim E.S.; CHIH-HSIN YANG; Schuler M.; Popat S.; Miura S.; Heeke S.; Park K.; M?rten A.; Kim E.S.
臺大學術典藏	2021-04-23T05:56:26Z	Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Final analysis of the GioTag study	Hochmair M.J.;Morabito A.;Hao D.;Yang C.-T.;Soo R.A.;Chih-Hsin Yang;Gucalp R.;Halmos B.;M?Rten A.;Cufer T.; Hochmair M.J.; Morabito A.; Hao D.; Yang C.-T.; Soo R.A.; CHIH-HSIN YANG; Gucalp R.; Halmos B.; M?rten A.; Cufer T.
臺大學術典藏	2020-05-26T09:26:51Z	Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials	Shah R; Märten A; Massey D; Wind S; Wu Y.-L.; Dickgreber N; Okamoto I; Sebastian M; Huang Y; Hirsh V; Lu S; O'Byrne K; Feng J; Wu Y.-L.;Wind S;Massey D;M?rten A;Shah R;Dickgreber N;Okamoto I;Sebastian M;Huang Y;Hirsh V;Lu S;O'Byrne K;Feng J;Yamamoto N;Hu C.-P;Mok T;Geater S.L;Schuler M;Zhou C;Sequist L.V;Chih-Hsin Yang; CHIH-HSIN YANG; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N
臺大學術典藏	2020-05-26T09:26:42Z	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial	Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:32Z	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)	O?�Byrne K; Geater S.L; Zhou C; Massey D; Märten A; Lungershausen J; CHIH-HSIN YANG; Schuler M; Mok T; Yamamoto N; Huang Y; Lu S; Hu C.-P; Feng J; Sequist L.V; Hirsh V; Wu Y.-L; Chih-Hsin Yang;Lungershausen J;M?rten A;Massey D;Zhou C;Geater S.L;O??Byrne K;Yamamoto N;Mok T;Schuler M;Huang Y;Lu S;Feng J;Hu C.-P;Sequist L.V;Hirsh V;Wu Y.-L
臺大學術典藏	2020-05-26T09:26:27Z	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials	Park K.;Paz-Ares L; Chih-Hsin Yang;M?rten A;Peil B;Mok T;Boyer M;O'Byrne K;Yamamoto N;Hirsh V;Schuler M;Barrios C.H;Kato T;Tsai C.-M;Lee K.H;Zhang L;Orlov S;Geater S.L;Tan E.-H;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG; Paz-Ares L; Park K.
臺大學術典藏	2020-05-26T09:26:25Z	Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study	Märten A; Cufer T.; Cufer T.;M?rten A;Golembesky A;Wang L;Halmos B;Gucalp R;Chih-Hsin Yang;Soo R.A;Yang C.-T;Hao D;Morabito A;Hochmair M.J; Hochmair M.J; Morabito A; Hao D; Yang C.-T; Soo R.A; CHIH-HSIN YANG; Gucalp R; Halmos B; Wang L; Golembesky A
臺大學術典藏	2020-05-26T09:26:23Z	Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study	Cufer T.; Märten A; Wang L; Halmos B; Gucalp R; CHIH-HSIN YANG; Soo R.A; Yang C.-T; Hao D; Hochmair M.J;Morabito A;Hao D;Yang C.-T;Soo R.A;Chih-Hsin Yang;Gucalp R;Halmos B;Wang L;M?rten A;Cufer T.; Hochmair M.J; Morabito A
臺大學術典藏	2020-05-26T09:26:21Z	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer	Park K;Bennouna J;Boyer M;Hida T;Hirsh V;Kato T;Lu S;Mok T;Nakagawa K;O'Byrne K;Paz-Ares L;Schuler M;Sibilot D.M;Tan E.-H;Tanaka H;Wu Y.-L;Chih-Hsin Yang;Zhang L;Zhou C;M?rten A;Tang W;Yamamoto N.; Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N.

Showing items 1-10 of 12 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page